ReviewTranslational andrology and urology2024
Diagnostic status and new explorations in upper urinary tract urothelial carcinoma: a literature review.
Review in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making-A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Enhanced Endoscopic Imaging Technologies in Upper Urinary Tract Urothelial Tumors: Implications for Kidney-Sparing Surgery-A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- Beyond the stone: nephrolithiasis as a metabolic sentinel in upper tract urothelial carcinoma and papillary renal cell carcinoma: toward a risk-stratified management framework.International urology and nephrology · 2026Review
- Successful multidisciplinary management of non-muscle-invasive upper tract urothelial carcinoma in a patient with HIV and concurrent staghorn calculus: a case report.AIDS research and therapy · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Upper urinary tract urothelial carcinomas (UTUCs) are characterized by their obscure location, insidious onset, and propensity for early muscle-invasive and lymph node metastasis, resulting in a generally poor prognosis. Clinically, diagnosis primarily relies on urine cytology, computed tomography urography (CTU), and white light ureteroscopy (WL-URS). These methods, however, suffer from low sensitivity, high cost, inefficient testing, patient discomfort, surgery-related complications, and potential tumor implantation. This literature review summarizes the advantages and disadvantages of the existing diagnostic tools for UTUC and discusses promising advancements in the field. Methods: A comprehensive computer-assisted search, supplemented by literature tracing, was conducted to review publications on UTUCs diagnostics from the PubMed, Embase, and Web of Science databases covering the period from 2000 to August 2024. The research focused on synthesizing findings from the selected publications. Key Content and Findings: Over 100 studies were reviewed, spanning from traditional diagnostic methods like urine cytology, CTU, and WL-URS, as well as newer methods including endoscopic advances, biopsy methods, radiomics, immunocytology [urinary tumor cell (UTC) assay], urinary genetic tests (identifying chromosomal abnormalities, DNA mutations, DNA methylation, and RNA), and hematological and urinary tests for microRNAs (miRNAs) and proteins (plasma protein classifiers). While traditional methods have been extensively evaluated, they remain suboptimal in terms of effectiveness, safety, patient satisfaction, and cost. Emerging diagnostics and molecular markers show promise, such as the high sensitivity of the urinary UTC assay for early-stage tumors and the non-invasive nature of various urinary molecular tests, along with the high accuracy of plasma protein classifiers. However, these new tools generally lack thorough evaluation and are often restricted to reports from single institutions or simple differentiation of cancerous cases from controls under experimental conditions. Conclusions: Traditional diagnostic methods for UTUCs exhibit significant limitations, which newer tools and molecular markers are poised to address. However, comprehensive evaluations of these innovations are required to confirm their efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.